Provided By PR Newswire
Last update: Sep 22, 2025
Headline Summary: Board-certified plastic surgeon brings extensive expertise in facial anatomy and injectable treatments to support nationwide rollout of breakthrough hyaluronic acid technology. Partnership underscores Evolus' commitment to patient safety and provider education for their new FDA-approved filler line.
Read more at prnewswire.comNASDAQ:EOLS (10/14/2025, 11:38:34 AM)
6.175
+0.17 (+2.92%)
Find more stocks in the Stock Screener